Inmune Bio Files 8-K: Material Agreements & Board Changes
Ticker: INMB · Form: 8-K · Filed: Dec 9, 2024 · CIK: 1711754
| Field | Detail |
|---|---|
| Company | Inmune Bio, Inc. (INMB) |
| Form Type | 8-K |
| Filed Date | Dec 9, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $5.05 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, corporate-governance, filing
TL;DR
Inmune Bio signed a big deal, changed some rules for shareholders, and shuffled execs/directors. Big news.
AI Summary
On December 4, 2024, Inmune Bio, Inc. entered into a material definitive agreement related to its business operations. The company also reported on modifications to the rights of its security holders and changes in its board of directors and officer compensation. The filing includes financial statements and exhibits.
Why It Matters
This filing indicates significant corporate actions, including new agreements and potential changes affecting shareholder rights and executive compensation, which could impact the company's strategic direction and valuation.
Risk Assessment
Risk Level: medium — Material definitive agreements and changes in director/officer roles can introduce new risks or alter existing ones for the company and its investors.
Key Players & Entities
- Inmune Bio, Inc. (company) — Registrant
- December 4, 2024 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 001-38793 (identifier) — SEC File Number
- 47-5205835 (identifier) — IRS Employer Identification No.
- 225 NE Mizner Boulevard, Suite 640, Boca Raton, FL 33432 (address) — Principal Executive Offices
FAQ
What type of material definitive agreement did Inmune Bio, Inc. enter into?
The filing states that Inmune Bio, Inc. entered into a material definitive agreement, but the specific details of the agreement are not provided in the excerpt.
What are the key items reported in this 8-K filing?
The key items reported are entry into a material definitive agreement, material modifications to rights of security holders, departure/election of directors, appointment of officers, and compensatory arrangements, along with financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on December 4, 2024.
Where is Inmune Bio, Inc. incorporated?
Inmune Bio, Inc. is incorporated in Nevada.
What is the address of Inmune Bio, Inc.'s Principal Executive Offices?
The address of Inmune Bio, Inc.'s Principal Executive Offices is 225 NE Mizner Boulevard, Suite 640, Boca Raton, FL 33432.
Filing Stats: 993 words · 4 min read · ~3 pages · Grade level 10.2 · Accepted 2024-12-09 16:00:30
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share INMB The NASDAQ Stock Mar
- $5.05 — common stock with an exercise price of $5.05 under the Company's 2021 Stock Incentiv
Filing Documents
- ea0223776-8k_inmune.htm (8-K) — 41KB
- ea022377601ex4-1_inmune.htm (EX-99.1) — 20KB
- 0001213900-24-106919.txt ( ) — 238KB
- inmb-20241204.xsd (EX-101.SCH) — 3KB
- inmb-20241204_lab.xml (EX-101.LAB) — 33KB
- inmb-20241204_pre.xml (EX-101.PRE) — 22KB
- ea0223776-8k_inmune_htm.xml (XML) — 4KB
02 Departure
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 4, 2024, the Compensation Committee (the "Compensation Committee") of the Board of Directors (the "Board") of INmune Bio Inc. (the "Company") approved the issuance of an option to each of the Company's non-employee directors; Timothy Schroeder, J. Kelly Ganjei, Scott Juda and Marcia Allen (collectively, the "Optionees") to purchase 32,500 shares of the Company's common stock with an exercise price of $5.05 under the Company's 2021 Stock Incentive Plan (the "2021 Plan"). The options will become 100% vested and exercisable on December 5, 2026, the two-year anniversary of the grant date and expire on December 4, 2034. The Company has executed a nonqualified stock option agreement with the Optionees. On December 4, 2024, the Compensation Committee approved the issuance of options to Ramond J. Tesi, the Company's Chief Executive Officer, and David Moss, the Company's Chief Financial Officer, to purchase 226,000 and 223,000 shares of the Company's common stock, respectively, pursuant to incentive stock option agreements and the issuance of options to the Company's Chief Scientific Officer, Mark Lowdell to purchase 140,000 shares of the Company's common stock pursuant to a nonqualified stock option agreement. The options have an exercise price of $5.05 per share. The options were granted under the 2021 Plan, will become 100% vested and exercisable on December 5, 2026, the two-year anniversary of the grant date and expire on December 4, 2034. The forgoing summary of the option grants referenced above is not complete and qualified in its entirety by reference to the Company's standard form of nonqualified option agreement and standard form of incentive stock option agreement. Item 9.01. Financial Statements and Exhibits (d) Exhibits Number Description 4.1 Amendment No. 4 to Rights Agreement, da